期刊文献+

HPLC法测定氯诺昔康分散片的含量含量均匀度及溶出度 被引量:1

HPLC Determination of Lornoxicam Content Content Uniformity and Dissolution in Lornoxicam Dispersible Tablets
下载PDF
导出
摘要 目的建立氯诺昔康分散片含量、含量均匀度及溶出度的HPLC测定法。方法采用RH-HPLC法,色谱柱为KINGFUN-Eldath AQ-C18(4.6mm×250mm,5μm),流动相:0.05mol·L-1磷酸二氢钾溶液(每100ml加1ml冰醋酸)-甲醇(50∶50),流速为1.0ml·min^(-1),柱温:30℃,检测波长:383nm。结果氯诺昔康峰与各主要杂质峰分离度良好,氯诺昔康在2.84~45.40μg·ml^(-1)范围内与峰面积线性关系良好,回归方程为A=5.9476×104 C-1.6466×104,r=0.9999(n=6);平均加样回收率为100.47%,RSD为0.79%(n=9);重复性试验RSD为0.51%(n=6);供试品溶液在24h内稳定。结论本方法准确、灵敏、专属性强,适用于氯诺昔康分散片的质量控制。 Objective To establish an HPLC method to determine the lornoxicam content,content uniformity and dissolution in lornoxicam dispersible tablets.Methods The analysis was conducted on a KINGFUN-Eldath AQ-C18column(4.6mm×250mm,5μm)using a mobile phase of 0.05mol·L-1 potassium phosphate monobasic solution(1 ml acetic acid added to 100 ml solution)-methonal(50∶50).The flow rate was 1.0ml·min^(-1),the column temperature was 30℃and the detection wavelength was 383 nm.Results There was a good resolution rate between the peaks of lornoxicam and the main related substances.There was a good linear relationship between the peak area and the concentration of lornoxicam in the range of 2.84-45.40μg·ml^(-1).Regression equation could be expressed as A=5.9476×104 C-1.6466×104,r =0.9999(n =6).The average recovery was 100.47%(RSD=0.79%,n =9),whihe the RSD of the repeatability test was 0.51%(n =6).The solution remained stable for 24 h.Conclusion This method is specific,accurate and sensitive,which can be used for quality control of lornoxicam dispersible tablets.
作者 曹薇薇 王志平 CAO Wei-wei WANG Zhi-ping(Tangshan Institute for Food and Drug Control,Tangshan 063000,Chin)
出处 《解放军药学学报》 CAS CSCD 2016年第6期533-534,537,共3页 Pharmaceutical Journal of Chinese People's Liberation Army
关键词 氯诺昔康分散片 含量测定 含量均匀度 溶出度 HPLC lornoxicam dispersible tablets content determination content uniformity dissolution HPLC
  • 相关文献

参考文献5

二级参考文献18

  • 1付桂英,郭华,左秀萍,高晖,温明铃.注射用氯诺昔康的制备及稳定性研究[J].中国药房,2005,16(9):671-673. 被引量:5
  • 2Radhofer WS, Dittrich P. Determination of the novel nonsteroidal antiinflammatory drug lomoxicam and its main metabolite in plasma and synovial fluid. J Chromatogr B, 1998,707 ( 1 - 2 ) : 151.
  • 3CHENZhong—wamg(陈忠望).Two kinds 0f selective COX—2 inkbitors(两种新的选择性环氧合酶抑制剂)[J].Foreign Med Sci Pharm(国外医学一药学分册),1997,24(3):168-168.
  • 4Julia A Balfour, Andrew Fitton, Lee B BarradeIl. Lomoxicam, a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions.Drugs, 1996,51 (4) :639.
  • 5陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 6Balfour JA,Fitton A,Barradell LB.Lornoxicam:review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions[J].Drugs,1996,51(4):639.
  • 7Rosenow DE,Albrechtsen M,Stolke D.A comparison of patient-controlled analgesia with lornoxicam versus morphine in patients undergoing lumbar disk surgery[J].Anesth Analg 1998,86(5):1045.
  • 8The Merck index:an encyclopedia of chemicals,drugs,and biologicals[DB/OL].Whitehouse Station,NJ.Merck,2001.13rd ED
  • 9Florence AT,Attwood D.Physicochemical principles of pharmacy[M].ed 3.Houndmills,Basingstoke:Hampshire Macmillan Press,1998:162-163.
  • 10Zhao L,Li P,Yalkowsky SH.Solubilization of fluasterone[J].J Pharm Sci,1999,88:967.

共引文献7

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部